Education
About Us
Working with TipRanks
Follow Us
Pharming Group N.V. (DE:PHGN)
XETRA:PHGN
PHGN Stock Chart & Stats
€1.42
€0.01(1.21%)
At close: 4:00 PM EST
€1.42
€0.01(1.21%)
Day’s Range― - ―
52-Week Range€0.67 - €2.45
Previous CloseN/A
Volume0.00
Average Volume (3M)11.21K
Market Cap
€931.46M
Enterprise Value€1.06B
Total Cash (Recent Filing)€153.15M
Total Debt (Recent Filing)€98.58M
Price to Earnings (P/E)408.6
Beta0.63
Next Earnings
May 07, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding701,404,050
10 Day Avg. Volume3,832
30 Day Avg. Volume11,210
Financial Highlights & Ratios
PEG Ratio-3.33
Price to Book (P/B)3.72
Price to Sales (P/S)3.10
P/FCF Ratio23.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€420.05M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins (~80–90% historically, with a reported improvement to 93%) indicate strong product economics typical of specialty biologics. High gross margins support durable cash generation, enable reinvestment in R&D and commercialization, and provide a buffer against pricing or COGS pressure over the medium term.
Recovered Cash GenerationA material recovery to positive operating cash flow in 2025 (reported $32m) and free cash flow roughly matching net income improves the company's internal funding capacity. Durable positive cash generation reduces reliance on external financing, supports late-stage trials and commercialization, and increases resilience against revenue swings over 2–6 months.
Commercial Momentum And PipelineTwo commercial products delivering high double-digit growth provide diversified, durable revenue streams rather than dependence on a single medicine. Coupled with an advancing late-stage pipeline (Phase II PIDs and registrational KL1333), this combination creates multiple structural growth levers and lowers single-product execution risk over the medium term.
Bears Say
Revenue VolatilityA pullback in 2025 after earlier expansion highlights an inconsistent top-line trajectory. For a rare-disease company, unstable revenue complicates forecasting, payer negotiations, and commercial investment pacing, making it harder to sustain steady rollout and fund pipeline priorities without external support.
Fragile ProfitabilityThe swing between multi-year profits and losses and only a marginal 2025 profit implies earnings are sensitive to volume and cost shifts. Thin operating and net margins mean minor adverse events (reimbursement setbacks, cost inflation) could erase profits, limiting durable returns and constraining reinvestment capacity.
Market Withdrawal RiskWithdrawing RUCONEST from some European markets is a structural contraction in geographic footprint. That reduces addressable patient pools and scale economies, weakening revenue diversity and long-term commercial leverage in affected regions, and may slow global growth and bargaining power with payers.
Pharming Group News
PHGN FAQ
What was Pharming Group N.V.’s price range in the past 12 months?
Pharming Group N.V. lowest stock price was €0.67 and its highest was €2.45 in the past 12 months.
What is Pharming Group N.V.’s market cap?
Pharming Group N.V.’s market cap is €931.46M.
When is Pharming Group N.V.’s upcoming earnings report date?
Pharming Group N.V.’s upcoming earnings report date is May 07, 2026 which is in 47 days.
How were Pharming Group N.V.’s earnings last quarter?
Pharming Group N.V. released its earnings results on Mar 12, 2026. The company reported €0.006 earnings per share for the quarter, beating the consensus estimate of €0.002 by €0.004.
Is Pharming Group N.V. overvalued?
According to Wall Street analysts Pharming Group N.V.’s price is currently Overvalued.
Does Pharming Group N.V. pay dividends?
Pharming Group N.V. does not currently pay dividends.
What is Pharming Group N.V.’s EPS estimate?
Pharming Group N.V.’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group N.V. have?
Pharming Group N.V. has 701,404,050 shares outstanding.
What happened to Pharming Group N.V.’s price movement after its last earnings report?
Pharming Group N.V. reported an EPS of €0.006 in its last earnings report, beating expectations of €0.002. Following the earnings report the stock price went down -4.467%.
Which hedge fund is a major shareholder of Pharming Group N.V.?
Currently, no hedge funds are holding shares in DE:PHGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHGN Company Deck
PHGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.View all DE:PHGN earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---